血清肿瘤标志物联合检测在胰腺癌诊断中的应用价值  

Application of combined test for serum tumor markers in diagnosis of pancreatic adenocarcinoma

作　　者：杨锐[1] 太京华[1] 金珍婧[1] 潘留兰[1] 牟文玲 

机构地区：[1]吉林大学第二医院消化内科,长春130041

出　　处：《中国生物制品学杂志》2012年第3期361-363,共3页Chinese Journal of Biologicals

摘　　要：目的探讨血清肿瘤标志物糖类抗原(Carbohydrate antigen,CA)242(CA242)、CA724联合检测在胰腺癌诊断中的应用价值。方法采用放射免疫法分别检测34例胰腺癌、26例慢性胰腺炎患者及60名健康体检者的血清CA242和CA724水平。结果进展期胰腺癌组血清中CA242和CA724的水平均明显高于早期胰腺癌组、慢性胰腺炎组和正常对照组(P均<0.01),早期胰腺癌组、慢性胰腺炎组和正常对照组之间CA242和CA724的水平差异无统计学意义(P>0.05);胰腺癌患者血清中CA242、CA724单独和联合检测的敏感性分别为61.7%、57.3%和84.9%,特异性分别为91.0%、87.6%和90.3%。结论血清肿瘤标志物CA242、CA724的定量测定是诊断胰腺癌敏感、特异的指标,但其早期敏感性较差;其测定结果与胰腺癌的分期及预后明显相关;联合检测可使其敏感性明显提高,而特异性无明显改变。Objective To investigate the application of combined test for serum tumor markers,i.e.carbohydrate antigens（CA） 242 and 724,in diagnosis of pancreatic adenocarcinoma.Methods The CA242 and CA724 levels in sera of 34 patients with pancreatic adenocarcinoma,26 patients with chronic pancreatitis and 60 healthy persons were determined by radioimmunoassay（RIA）.Results The CA242 and CA724 levels in sera of patients with pancreatic adenocarcinoma at progressive stage were significantly higher than those at early stage and those of patients with chronic pancreatitis and healthy persons（each P 0.01）.However,the levels showed no significant difference in the patients with pancreatic adenocarcinoma at early stage,chronic pancreatitis and healthy persons（P 0.05）.The sensitivities of determination of CA242,CA724 and CA242 ＋ CA724 in patients with pancreatic adenocarcinoma were 61.7%,57.3% and 84.9%,while the specificities were 91.0%,87.6% and 90.3%,respectively.Conclusion Quantitative determination of CA242 and CA724 were sensitive and specific for diagnosis of pancreatic adenocarcinoma,of which the sensitivity for early diagnosis was relatively low.The determination result was significantly related to the stage and prognosis of pancreatic adenocarcinoma.The sensitivity of combined test for CA242 and CA724 increased significantly,while the specificity showed no significant change.

关 键 词：肿瘤标志物 胰腺肿瘤 诊断 

分 类 号：R735.9[医药卫生—肿瘤]